AU2019398516B2 - Bicyclic peptide ligands specific for MT1-MMP - Google Patents
Bicyclic peptide ligands specific for MT1-MMPInfo
- Publication number
- AU2019398516B2 AU2019398516B2 AU2019398516A AU2019398516A AU2019398516B2 AU 2019398516 B2 AU2019398516 B2 AU 2019398516B2 AU 2019398516 A AU2019398516 A AU 2019398516A AU 2019398516 A AU2019398516 A AU 2019398516A AU 2019398516 B2 AU2019398516 B2 AU 2019398516B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- harg
- referred
- eca
- lfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025271131A AU2025271131A1 (en) | 2018-12-13 | 2025-11-21 | Bicyclic peptide ligands specific for MT1-MMP |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820286.1 | 2018-12-13 | ||
| GBGB1820286.1A GB201820286D0 (en) | 2018-12-13 | 2018-12-13 | Bicyclic peptide ligands specific for mt1-mmp |
| GBGB1906534.1A GB201906534D0 (en) | 2019-05-09 | 2019-05-09 | Bicycle peptide ligands specific for MT1-MMP |
| GB1906534.1 | 2019-05-09 | ||
| PCT/GB2019/053540 WO2020120984A1 (en) | 2018-12-13 | 2019-12-13 | Bicyclic peptide ligands specific for mt1-mmp |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025271131A Division AU2025271131A1 (en) | 2018-12-13 | 2025-11-21 | Bicyclic peptide ligands specific for MT1-MMP |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019398516A1 AU2019398516A1 (en) | 2021-08-05 |
| AU2019398516B2 true AU2019398516B2 (en) | 2025-09-04 |
Family
ID=68988066
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019398516A Active AU2019398516B2 (en) | 2018-12-13 | 2019-12-13 | Bicyclic peptide ligands specific for MT1-MMP |
| AU2025271131A Pending AU2025271131A1 (en) | 2018-12-13 | 2025-11-21 | Bicyclic peptide ligands specific for MT1-MMP |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025271131A Pending AU2025271131A1 (en) | 2018-12-13 | 2025-11-21 | Bicyclic peptide ligands specific for MT1-MMP |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220024982A1 (https=) |
| EP (1) | EP3894010A1 (https=) |
| JP (2) | JP2022513806A (https=) |
| KR (1) | KR20210123295A (https=) |
| CN (1) | CN113507962A (https=) |
| AU (2) | AU2019398516B2 (https=) |
| BR (1) | BR112021011340A2 (https=) |
| CA (1) | CA3122669A1 (https=) |
| IL (2) | IL326448A (https=) |
| MX (1) | MX2021006991A (https=) |
| SG (1) | SG11202106081YA (https=) |
| WO (1) | WO2020120984A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820288D0 (en) * | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| AU2022206577A1 (en) * | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| MX2024003876A (es) * | 2021-09-29 | 2024-04-19 | Conjustar Zhuhai Biologics Co Ltd | Conjugado farmaco-polipeptido triciclico y sus aplicaciones. |
| WO2023088236A1 (zh) * | 2021-11-16 | 2023-05-25 | 海思科医药集团股份有限公司 | Mt1-mmp的双环肽配体及其缀合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016067035A1 (en) * | 2014-10-29 | 2016-05-06 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
| EP3192802A1 (en) * | 2016-01-18 | 2017-07-19 | Bicycle Therapeutics Limited | Stabilized peptide derivatives |
| WO2018127699A1 (en) * | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
| GB0913775D0 (en) * | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| WO2013142229A1 (en) * | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| GB201306623D0 (en) * | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| GB201607827D0 (en) * | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| GB201713560D0 (en) * | 2017-08-23 | 2017-10-04 | Bicycle Therapeutics Ltd | Peptide ligands for binding to Mt1-Mmp |
| US20190389907A1 (en) * | 2016-12-23 | 2019-12-26 | Bicycletx Limited | Peptide ligands for binding to mt1-mmp |
| US10857196B2 (en) * | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
-
2019
- 2019-12-13 WO PCT/GB2019/053540 patent/WO2020120984A1/en not_active Ceased
- 2019-12-13 CA CA3122669A patent/CA3122669A1/en active Pending
- 2019-12-13 AU AU2019398516A patent/AU2019398516B2/en active Active
- 2019-12-13 CN CN201980090137.1A patent/CN113507962A/zh active Pending
- 2019-12-13 MX MX2021006991A patent/MX2021006991A/es unknown
- 2019-12-13 US US17/309,626 patent/US20220024982A1/en active Pending
- 2019-12-13 IL IL326448A patent/IL326448A/en unknown
- 2019-12-13 JP JP2021533584A patent/JP2022513806A/ja active Pending
- 2019-12-13 SG SG11202106081YA patent/SG11202106081YA/en unknown
- 2019-12-13 KR KR1020217021606A patent/KR20210123295A/ko not_active Ceased
- 2019-12-13 BR BR112021011340-1A patent/BR112021011340A2/pt unknown
- 2019-12-13 EP EP19824380.0A patent/EP3894010A1/en active Pending
-
2021
- 2021-06-10 IL IL283873A patent/IL283873B1/en unknown
-
2024
- 2024-05-24 JP JP2024084502A patent/JP2024119862A/ja active Pending
-
2025
- 2025-11-21 AU AU2025271131A patent/AU2025271131A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016067035A1 (en) * | 2014-10-29 | 2016-05-06 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
| EP3192802A1 (en) * | 2016-01-18 | 2017-07-19 | Bicycle Therapeutics Limited | Stabilized peptide derivatives |
| WO2018127699A1 (en) * | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| IL283873B1 (en) | 2026-03-01 |
| IL326448A (en) | 2026-04-01 |
| WO2020120984A1 (en) | 2020-06-18 |
| US20220024982A1 (en) | 2022-01-27 |
| KR20210123295A (ko) | 2021-10-13 |
| MX2021006991A (es) | 2021-10-13 |
| JP2024119862A (ja) | 2024-09-03 |
| CN113507962A (zh) | 2021-10-15 |
| CA3122669A1 (en) | 2020-06-18 |
| JP2022513806A (ja) | 2022-02-09 |
| BR112021011340A2 (pt) | 2021-09-08 |
| AU2019398516A1 (en) | 2021-08-05 |
| EP3894010A1 (en) | 2021-10-20 |
| SG11202106081YA (en) | 2021-07-29 |
| IL283873A (en) | 2021-07-29 |
| AU2025271131A1 (en) | 2025-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019398516B2 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| AU2019398722B2 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| US12491253B2 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| US20240000957A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | |
| US20240173422A1 (en) | Bicyclic peptide ligand drug conjugates | |
| WO2020128526A1 (en) | Bicyclic peptide ligands specific for pd-l1 | |
| EA046487B1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp | |
| US20260124312A1 (en) | Bicyclic peptide ligands specific for epha2 | |
| EA046810B1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp | |
| HK40120938A (en) | Bicyclic peptide ligands specific for epha2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: BICYCLETX LIMITED Free format text: FORMER NAME(S): BICYCLETX LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) |